From the beginning of this year my life has been a roller coaster ride, leaving the hectic life, what I found is Bangalore is better compared to my life in Delhi. From last month I have been looking at a different trend, I started reading about Big pharma investment in emerging markets, what i am looking at is many of the big pharma's in the last 2-3 years have started collaboration with the Turkish companies or rather buying them out, and some for instance like out of the major top 20, Novartis last month announced that it is going to start its R&D in Turkey and today’s latest news is Amgen bought 95% stakes Turkish Drug maker Mustafa Nevzat for $700 Million. After china being the favorite destination in Asia for big pharma’s emerging market strategy, I feel that likewise Turkey is becoming key destination for penetration into North Africa and middle east emerging market strategy for Big pharma. Amgen of course with this deal has become part of large pharma with generic arm and what I believe that in coming 6-7 years will promote its biosimilar arm through the generic divisions which it will perhaps expand from turkey to other parts of Europe, as from olden days (Biblical era) Turkey was gateway to both Europe, Africa and Asia…………
No comments:
Post a Comment